The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
|Slideshows|July 24, 2017
4 Neurology Apps to Empower Older Patients
Author(s)Veronica Hackethal, MD
These apps are designed to improve treatment adherence, language skills, symptom tracking, communication, and other helpful functions.
Advertisement
Advertisement
Related to this article
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Fast track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
3
How MS Understanding Has Evolved: Activity, Impact, and Progression
4
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
5